Navigation Links
Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/10/2009

s."

Operational Key Events:

  • Raised $31.0 million from a registered direct offering that yielded $29.0 million in cash, net of $2.0 million of offering costs

  • Elected Ginger D. Constantine, M.D. to the Company's Board of Directors

  • FDA appointed Arthritis Advisory Committee recommended marketing approval for KRYSTEXXA

  • Presented six abstracts (two oral presentations and four posters) about KRYSTEXXA at the European League Against Rheumatism (EULAR) 2009 Annual Congress addressing various aspects of treatment failure gout.

  • Received a complete response letter from the FDA on July 31, 2009 stating that the FDA cannot at this time approve the BLA for KRYSTEXXA as a treatment for chronic gout in patients refractory to conventional therapy. The complete response letter cited deficiencies with the CMC section of the BLA and also provided the current draft of the proposed labeling and further guidance regarding a Risk Evaluation and Mitigation Strategy (REMS). We expect to resubmit our BLA to the FDA in early 2010 to respond to the FDA's complete response letter.

  • Received notification from the FDA of a tentative meeting date scheduled for mid-September 2009 to discuss the complete response letter issued by the FDA in response to the "Type A" Meeting request filed by the Company.

Financial Results of Operations for the Three Months Ended June 30, 2009

Total revenues for the second quarter of 2009 were $0.7 million compared with $0.4 million for the second quarter of 2008, an increase of $0.3 million. The increase is primarily the result of higher product sales of oxandrolone, our authorized generic product that promotes weight gain f
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
2. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
3. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
4. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
5. Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
6. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... Jose, California (PRWEB) March 30, 2015 ... Defined as radioactive isotopes, radiopharmaceuticals are used as ... The global market for radiopharmaceuticals is driven by ... procedures in the field of cardiology, neurology, pulmonology, ... supported by the well-established use of radioisotopes in ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 South Coast Surety ... a Surety Bond Representative. Richard has been known to the ... decade. , Richard attended the University of Georgia, majoring in ... decades in the sales and sales management of business equipment ... , Most recently, Richard was a senior officer with ...
(Date:3/30/2015)... DC (PRWEB) March 30, 2015 Daily ... toll on the face, causing wrinkles, folds and other ... invasive techniques empower men and women to hit the ... time. Today, there’s a nip, tuck or hack to ... of Facial Plastic and Reconstructive Surgery (AAFPRS) explores ...
(Date:3/30/2015)... States (PRWEB) March 30, 2015 Poo puts ... anything that could be better than Paleo, or better than ... out Poo - just released on the app store! ... step counting, there is a whole other half to that ... , With Poo, users do the dirty work, and then ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 Mid-America ... mobile library of medications used in behavioral health ... iPhone, iPad and Android—is a convenient, electronic version ... since 1999. The useful resource provides up-to-date information ... dosage and frequency, side effects, emergency conditions, cautions, ...
Breaking Medicine News(10 mins):Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 2Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 3Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 4Health News:Richard Ford Joins South Coast Surety Contract Surety Team 2Health News:New AAFPRS Infographic Addresses Concerns and Provides Aging Face Solutions 2Health News:Popular Publication on Behavioral Health Medications Now An App 2
... (BPA) -- a substance that may have harmful health ... register receipts, scientists are reporting. The recycling of those ... of paper napkins, toilet paper, food packaging and other ... for cashiers and other people who routinely handle thermal ...
... a major earthquake experienced high levels of post-traumatic stress disorder ... affected, according to a study published in the November issue ... led by the West China School of Nursing and West ... 12 to 20 years of age three months after the ...
... a biochemist at the University of the Basque Country (UPV/EHU), ... term, the early diagnosis of cancer of the large intestine ... known as peptidases and their activity (working rate): she has ... at different stages of the disease. If these fluctuations could ...
... , WEDNESDAY, Oct. 26 (HealthDay News) -- People ... attempt to boost their social status, a new study suggests. ... portions with higher social standing. For example, study participants believed ... social status than those who chose a medium or small ...
... -- A new potential leukemia therapy targets only cancer ... chemotherapy treatments affect cancer cells and healthy cells, causing ... anxiety and depression. This research is being presented ... Annual Meeting and Exposition in Washington, D.C., Oct. 23 ...
... It is known that a high proportion of dense breast ... high risk of breast cancer. But the role of non-dense ... published in BioMed Central,s open access journal Breast Cancer ... fibroglandular tissue, and fat, and shows that large areas of ...
Cached Medicine News:Health News:Teenage girls and senior students suffered highest levels of PTSD after major earthquake 2Health News:Teenage girls and senior students suffered highest levels of PTSD after major earthquake 3Health News:Steps being taken towards achieving an early diagnosis of cancer of the large intestine 2Health News:Steps being taken towards achieving an early diagnosis of cancer of the large intestine 3Health News:Larger Food Portions May Be Seen as Status Symbols 2
(Date:3/30/2015)... TEL AVIV, Israel , March 30, 2015   ... , announced the closing of $12.5 million in new financing ... the Viola Group. The funding will further GlassesUSA,s aggressive business ... the growing global market of online eyewear, both B2C and ... Daniel Rothman , COO Eldad Rothman , and ...
(Date:3/30/2015)... 2015  Zimmer Holdings, Inc. (NYSE and SIX: ... ("EC") has conditionally cleared Zimmer,s proposed acquisition of ... upon Zimmer entering into agreements with a suitable ... package previously submitted to the EC.  Zimmer expects ... term.  As previously announced, the proposed transaction also ...
(Date:3/30/2015)... , March 30, 2015  The future ... to involve more data analytics; new, more precise ... imaging and motion management techniques.  Some 150 researchers ... ideas last week at a symposium on research ... ).     "Researchers are developing, testing, ...
Breaking Medicine Technology:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 2Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 3Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 4Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 5Radiation Oncology Researchers Glimpse the Future of Cancer Care 2Radiation Oncology Researchers Glimpse the Future of Cancer Care 3Radiation Oncology Researchers Glimpse the Future of Cancer Care 4Radiation Oncology Researchers Glimpse the Future of Cancer Care 5Radiation Oncology Researchers Glimpse the Future of Cancer Care 6
The Streck-MD-Pack is specially designed for use on Coulter® MD Series instruments. Each pack contains diluent and lysing agent. The shelf life is one year from date of manufacture....
A lytic reagent manufactured for the simultaneous quantitative determinations of hemoglobin and white blood cells. Streck-Lysing Agent III is for use on the Abbott CELL-DYN® 1400 and 1600. The sh...
Streck-Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3000. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Medicine Products: